WallStSmart

AstraZeneca PLC (AZN)vsAlpha Tau Medical Ltd (DRTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

DRTS

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+8.2%)

Margin of Safety

+8.2%

Fair Value

$194.77

Current Price

$185.95

$8.82 discount

UndervaluedFair: $194.77Overvalued

Intrinsic value data unavailable for DRTS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

DRTS1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

DRTS4 concerns · Avg: 3.8/10
Price/BookValuation
12.1x4/10

Trading at 12.1x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$844.55M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : DRTS

The strongest argument for DRTS centers on Debt/Equity.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : DRTS

The primary concerns for DRTS are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

AZN profiles as a mature stock while DRTS is a value play — different risk/reward profiles.

DRTS carries more volatility with a beta of 1.20 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

AZN scores higher overall (64/100 vs 17/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Alpha Tau Medical Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.

Visit Website →

Want to dig deeper into these stocks?